Allergy Therapeutics PLC Results of mite immunotherapy Acarovac PlusT
July 08 2016 - 2:00AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
08 July 2016
8 July 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Allergy Therapeutics announces publication of 1-year follow up
results of its mite allergoid immunotherapy Acarovac Plus(TM)
Significant decreases in symptom scores reported with Acarovac
Plus
Product treatment was proven to be well tolerated and safe
Allergy Therapeutics (AIM:AGY), the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, today
announces the publication of a 1-year follow-up study of patients
using Acarovac Plus(TM), its unique, microcrystalline
tyrosine-adsorbed, house dust mite-allergoid subcutaneous
immunotherapy in the peer-review journal Immunotherapy.
A previous study in 2014, led by Dr Albert Roger, Director of
the Allergy Unit at Universitari Hospital Trias I Pujol, Badalona,
Spain, assessed the tolerability and safety of Acarovac Plus(TM) in
patients with respiratory allergy to Dermatophagoides pteronyssinus
under conditions of normal clinical practice. This 1-year follow-up
investigation, with the existing patient pool and testing regimen,
assessed effectiveness using a nasal provocation test and
measurement of immunological markers that are indicative of
immunotherapy success.
A statistically significant reduction in symptom scores was
observed at both follow-up visits (four weeks and one year), with
>50% reduction in symptom scores recorded after one year.
Moreover, significant improvements in immunological markers were
noted at the follow-up visits. Patients reported statistically
significant improvements in satisfaction scores after one year in
relation to overall effectiveness and convenience of the
treatment.
2016 has seen a significant increase in sales of Acarovac
Plus(TM) to over EUR 1 million in key markets Spain and Portugal,
compared to 2015. Sales of house dust mite immunotherapy are
expected to increase rapidly over the coming years with over 20% of
the population in Europe experiencing an allergic reaction to house
dust mites. Therefore, Allergy Therapeutics is continuing to
develop Acarovac Quattro(TM), an ultra-short course therapy
utilising the adjuvant monophosphoryl lipid A (MPL), which is used
in the Company's successful Pollinex Quattro product range
currently in late stage development in Europe and the US to
complement Acarovac Plus(TM).
Commenting on the publication, Dr Albert Roger, principal
investigator for the study, said: "The successful clinical results
in the 1-year follow-up study clearly demonstrate the effective
treatment of house dust mite allergy by Acarovac Plus(TM). We also
observed significant decreases in symptom scores and improvement in
nasal sensitivity immediately after the up dosing phase of one
month and a high rate of patient satisfaction early in
treatment."
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics,
said: "This data further reinforces the benefits of Acarovac
Plus(TM) in the perennial allergy vaccine market. Using maintenance
injections six weeks apart, Acarovac Plus(TM) has been shown to
decrease the symptoms of house dust mite allergy one year after
treatment. This dosing regime has the potential to improve the
adherence and compliance that is essential for a successful
treatment. Acarovac Plus(TM) bolsters our portfolio of allergy
immunotherapy products on the market in Europe and we look forward
to continued good growth."
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura
Thornton
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Company sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Company employs c.420 employees and is listed on
the London Stock Exchange (AIM:AGY).
For more information, please see
www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALFFEIDTIDIIR
(END) Dow Jones Newswires
July 08, 2016 02:00 ET (06:00 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024